Dartmouth College

Dartmouth Digital Commons
Dartmouth Scholarship

Faculty Work

12-1-2021

Implementation facilitation to introduce and support emergency
department-initiated buprenorphine for opioid use disorder in high
need, low resource settings: protocol for multi-site
implementation-feasibility study
Ryan P. McCormack
NYU Grossman School of Medicine

John Rotrosen
NYU Grossman School of Medicine

Phoebe Gauthier
Geisel School of Medicine at Dartmouth

Gail D’Onofrio
Yale School of Medicine

David A. Fiellin
Yale School of Medicine
Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa
See next page for additional authors

Dartmouth Digital Commons Citation
McCormack, Ryan P.; Rotrosen, John; Gauthier, Phoebe; D’Onofrio, Gail; Fiellin, David A.; Marsch, Lisa A.;
Novo, Patricia; Liu, David; Edelman, E. Jennifer; Farkas, Sarah; Matthews, Abigail G.; Mulatya, Caroline;
Salazar, Dagmar; Wolff, Jeremy; Knight, Randolph; Goodman, William; and Hawk, Kathryn, "Implementation
facilitation to introduce and support emergency department-initiated buprenorphine for opioid use
disorder in high need, low resource settings: protocol for multi-site implementation-feasibility study"
(2021). Dartmouth Scholarship. 4170.
https://digitalcommons.dartmouth.edu/facoa/4170

This Article is brought to you for free and open access by the Faculty Work at Dartmouth Digital Commons. It has
been accepted for inclusion in Dartmouth Scholarship by an authorized administrator of Dartmouth Digital
Commons. For more information, please contact dartmouthdigitalcommons@groups.dartmouth.edu.

Authors
Ryan P. McCormack, John Rotrosen, Phoebe Gauthier, Gail D’Onofrio, David A. Fiellin, Lisa A. Marsch,
Patricia Novo, David Liu, E. Jennifer Edelman, Sarah Farkas, Abigail G. Matthews, Caroline Mulatya,
Dagmar Salazar, Jeremy Wolff, Randolph Knight, William Goodman, and Kathryn Hawk

This article is available at Dartmouth Digital Commons: https://digitalcommons.dartmouth.edu/facoa/4170

(2021) 16:16
McCormack et al. Addict Sci Clin Pract
https://doi.org/10.1186/s13722-021-00224-y

Addiction Science &
Clinical Practice
Open Access

STUDY PROTOCOL

Implementation facilitation to introduce
and support emergency department‑initiated
buprenorphine for opioid use disorder
in high need, low resource settings: protocol
for multi‑site implementation‑feasibility study
Ryan P. McCormack1* , John Rotrosen1, Phoebe Gauthier2, Gail D’Onofrio3, David A. Fiellin3,5, Lisa A. Marsch2,
Patricia Novo1, David Liu4, E. Jennifer Edelman5, Sarah Farkas1, Abigail G. Matthews6, Caroline Mulatya6,
Dagmar Salazar6, Jeremy Wolff6, Randolph Knight7, William Goodman8 and Kathryn Hawk3

Abstract
Background: For many reasons, the emergency department (ED) is a critical venue to initiate OUD interventions. The
prevailing culture of the ED has been that substance use disorders are non-emergent conditions better addressed
outside the ED where resources are less constrained. This study, its rapid funding mechanism, and accelerated timeline originated out of the urgent need to learn whether ED-initiated buprenorphine (BUP) with referral for treatment
of OUD is generalizable, as well as to develop strategies to facilitate its adoption across a variety of ED settings and
under real-world conditions. It both complements and uses methods adapted from Project ED Health (CTN-0069), a
Hybrid Type 3 implementation-effectiveness study of using Implementation Facilitation (IF) to integrate ED-initiated
BUP and referral programs.
Methods: ED-CONNECT (CTN 0079) was a three-site implementation study exploring the feasibility, acceptability,
and impact of introducing ED-initiated BUP in rural and urban settings with high-need, limited resources, and different staffing structures. We used a multi-faceted approach to develop, introduce and iteratively refine site-specific ED
clinical protocols and implementation plans for opioid use disorder (OUD) screening, ED-initiated BUP, and referral
for treatment. We employed a participatory action research approach and use mixed methods incorporating data
derived from abstraction of medical records and administrative data, assessments of recruited ED patient-participants, and both qualitative and quantitative inquiry involving staff from the ED and community, patients, and other
stakeholders.
Discussion: This study was designed to provide the necessary, time-sensitive understanding of how to identify OUD
and initiate treatment with BUP in the EDs previously not providing ED-initiated BUP, in communities in which this
intervention is most needed: high need, low resource settings.
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Trial registration: The study was prospectively registered on ClinicalTrials.gov (NCT03544112) on June 01, 2018: https://
clinicaltrials.gov/ct2/show/NCT03544112.
Keywords: Buprenorphine, Implementation science, Emergency service, Opioid use disorder

Background
The opioid epidemic has reached a critical state, drawing
widespread attention and support to address this public health crisis [1–3]. The emergency department (ED)
offers a low barrier venue to initiate opioid use disorder
(OUD) treatment and referral given the 24/7/365 availability for individuals with untreated OUD who often lack
other sources of healthcare. In the US, ED visits associated with opioids doubled between 2004 and 2014, and
visits for opioid overdose increased by approximately
30% from July 2016 through September of 2017 [4]. A
recent analysis of over 17,000 ED patients who survived
an opioid overdose demonstrated this population to
have a 5% annual mortality rate and that only one-third
received opioid agonist treatment with buprenorphine
(BUP) or methadone within the year. Importantly, mortality was reduced by 59% among patients who received
agonist treatment for OUD [5]. Through a landmark
3-arm randomized trial of 329 opioid dependent patients,
D’Onofrio et al. demonstrated the feasibility, safety, and
efficacy of initiating treatment with BUP in an urban ED
[6]. Although momentum to initiate BUP for the treatment of OUD in the ED is building, adoption has been
limited by the strong prevailing culture to defer initiating
substance use interventions to other treatment settings
[7]. This culture, combined with nearly overwhelming
logistical barriers, including federal regulations restricting BUP prescribing, limited accessibility of urgent OUD
referral opportunities, as well as time, space, and other
resource constraints inherent to the ED setting have limited uptake of ED-initiated BUP and referral. Meanwhile,
the worsening opioid epidemic is decimating communities small and large without regard to sex, race, ethnicity,
or socioeconomic status [4].
Rationale for study design
This manuscript describes the protocol, including the
design considerations and methods, of a study that examined the implementation of new clinical protocols to
initiate BUP for the treatment of OUD in 3 high need,
low resource EDs. This study resulted from the need to
quickly mobilize the resources of NIDA to translate evidence and interventions generated and tested in large,
urban, resource-rich academic settings to EDs with
high need for treating a growing population with OUD
but limited resources. This study concept emerged to

rapidly close the research to practice gap in the context
of a recent randomized controlled trial finding that EDinitiated BUP is effective at improving 30-day treatment
engagement [6] and high need, low resource EDs who are
not equipped to initiate BUP in the ED. To overcome the
aforementioned barriers to programmatic adoption, we
planned to incorporate emerging technologies, specifically including a novel, injectable extended-release BUP
(XR-BUP) formulation (CAM2038) whose FDA-approval
was expected imminently at the time this study was initially conceptualized. Unique to CAM2038 is that it can
be administered on the first day of induction to provide
steady state BUP blood concentrations for seven days,
enough time to arrange for a follow-up appointment with
an outpatient BUP prescriber without treatment interruption. Through the robust CTN review structure, the
study concept and, subsequently, the study protocol were
developed and reviewed by the Protocol Review Board
and Data and Safety Monitoring Board. The Emmes
Company served as the Contract Research Organization
(CRO), providing data and statistical support and clinical coordinating services. The study was approved by the
Biomedical Research Alliance of New York (BRANY)
Institutional Review Board. The study was registered
on ClinicalTrials.gov (NCT03544112) on June 01, 2018:
https://clinicaltrials.gov/ct2/show/NCT03544112.

Study aims
1. To evaluate the feasibility and acceptability of implementing a clinical protocol for OUD screening and
BUP treatment initiation (sublingual or extended
release XR-BUP) and referral in EDs with limited
resources and high need.
2. To estimate the percentage and confidence intervals
of patients assessed, treated, and engaged in formal
addiction treatment at Day 30.

Study overview
The resulting study, CTN-0079: ED CONNECT: Emergency Department Connection to Care with Buprenorphine for OUD, was a three-site implementation
feasibility study employing mixed methods and a participatory action research approach to: (1) develop,
introduce, and iteratively refine site-specific clinical protocols for the initiation of BUP in the ED and referral for
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treatment of OUD and (2) evaluate both programmatic
implementation and patient-level effectiveness outcomes.
Prior to the study, none of the study sites, which included
a community hospital, a rural critical access hospital and
a large public hospital, had active ED-based BUP programs. The study builds on the aforementioned work by
D’Onofrio et al. [6] and complements their subsequent,
ongoing study, NIDA CTN-0069 Project ED Health, a
hybrid type-3 implementation-effectiveness trial being
conducted in 4 large, academic EDs that simultaneously
tests both the effectiveness of ED-initiated BUP and
referral as well as the Implementation Facilitation (IF)
strategy employed to implement programs to initiate
treatment for OUD in the ED [8].
The CTN-0079 study design and accelerated timeframe (Table 1) reflects the need to quickly implement
treatment to address an urgent public health crisis. Specifically, CTN-0069 Project ED Health study methods
were adapted, including IF procedures and instruments
for formative evaluation and assessments, to expedite
clinical and research implementation and to facilitate
comparisons across these studies being conducted in
markedly different ED settings [8]. Data were collected
by: (i) abstracting patient data from the electronic medical record (EMR) (primary outcome, clinical program
reach) (ii) conducting focus groups and qualitative interviews with approximately 60 key informants (providers/staff from the ED and community, patients, other
stakeholders) (iii) administering surveys of readiness to
approximately 150 ED and community OUD treatment
providers and staff, (iv) enrolling a minimum of 60 ED
patients who were candidates to receive ED-initiated

Table 1 Study timeline
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BUP for baseline and 30-day assessments and toxicology analysis, and (v) recording qualitative field notes on
implementation observations.
The study launched with the Pre-Implementation
Period, during which survey data were collected and
reviewed and initial site visits occurred to conduct
qualitative inquiry for the formative evaluation. The sixmonth formal programmatic evaluation period began
upon approval of each site’s clinical protocol. Investigators conducted a close-out assessment at the end of the
study using the same survey and qualitative methods as
were used during the formative evaluation. IF activities
were initiated following the formative evaluation and
continued throughout the duration of the trial to iteratively refine processes.

Site selection
The study was conducted in three clinical EDs in hospitals with high-needs and low resources to address
the opioid epidemic (as outlined in Table 2): Catholic Medical Center, Manchester NH; Valley Regional
Healthcare, Claremont, NH; and Bellevue Hospital
Center, New York, NY. Typically, site selection for CTN
studies is performed through a formal application process with criteria to support study feasibility, generalizability, and rigor. For this study, however, settings
with unique challenges to clinical implementation were
selected to inform a range of implementation strategies across heterogenous EDs settings. Two of the sites
were identified based on the high rates of opioid-overdose associated mortality in New Hampshire and an
absence of ability to initiate BUP for the treatment of
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Table 2 Site characteristics overview
Valley Regional Healthcare

Catholic Medical Center

Bellevue Hospital Center

Patient volume

Low (10 K annual ED visits)

Medium–High (35 K annual ED visits)

Very High (120 K annual ED visits)

Patient need

High
– High rates of OD; Fentanyl-only drug
use common

High
- High rates of OD; Fentanyl-only drug
use common

High
– High prevalence of medical-psychiatric
co-morbidity and social disadvantage

Setting

Rural

Urban with suburban and rural catchment zone

Urban

Institution

Private, critical access community
hospital

Private, community hospital

Municipal, Academic-Affiliated, Tertiary
Care Hospital and Level 1 Trauma
Center

Referral options

Low

Medium

High

ED Physician Staffing

Single coverage, non-EM trained; some Temporarily assigned, locums (non80 faculty members; 60 residents.
locums (non-permanent staff )
permanent staff ). Pending change to
Resident-driven model
new locums agency

ED ancillary staffing

– Social work services not available
in ED

– Permanent mid-level providers

– Limited ancillary and support staff

– No in-hospital addiction or psychiatric specialty coverage

– Limited social work support

– Extremely low nurse to patient ratios
(often 1:20 in ED) and hiring freeze
– Health coaches and volunteers screen
and provide brief interventions for
substance use

Space

No crowding

Unique site characteristics Extremely limited community treatment options (none known to ED
prior to study)

Significant overcrowding problem

Overcrowding is common

No ED champion. PI outside of ED.
Active policy prohibiting the use of
BUP in ED. Locum tenens staffing
model. No existing heath system
addictions care

Local expertise and partnerships exist.
Understaffed and fragmented health
system and referral network

OUD in the ED. At the time, New Hampshire had the
highest rate of fentanyl overdose mortality per capita
in the US coupled with having among the lowest rates
per capita of medication treatment providers and other
treatment resources for OUD [9]. The third, Bellevue
Hospital, adds a large public safety-net hospital in the
midst of a hiring freeze and that, at baseline, has considerably higher patient/nurse ratios (reaching 20:1)
and fewer ancillary staff than most private, community
or academic EDs. Common to each site is the large proportion of economically disadvantaged or otherwise
vulnerable patients served. Additionally, all sites have
limited ED resources for managing a high need OUD
patient population, including one ED without social
work coverage and very few outpatient OUD treatment referral options. Each hospital has differing ED
staffing structures; one site was changing locum tenens
staffing agencies at the time of site selection, such that
the ED director and all incoming providers would be
newly hired. Further, all three sites used different EMR
software platforms and all three announced plans to
change these systems during the study period. Lastly,
none offered ED-initiated BUP at the start of the study.
Together, these sites enable assessment of feasibility,
acceptability, sustainability and costs in heterogeneous settings including community, critical access, and

municipal EDs across rural to urban population densities with varying addiction treatment and research
resources.

Study components
Study components were divided into (1) implementation facilitation (participatory action research approach
using mixed methods), (2) evaluation of clinical protocol implementation (primary outcome and secondary
process outcomes), and (3) patient-participant level outcomes (secondary outcomes of effectiveness and acceptability). See Table 3.
Study populations
The study populations included: (1) Key informant participants to participate in the formative evaluation and IF,
(2) All ED Patients via administrative and health record
data examination to assess rates of screening, assessment,
eligibility determination, and (3) ED Patient-Participants
who were eligible for and willing to receive ED-initiated
BUP and signed written consent to participate in two
research visits.
Key informant participants were recruited from targeted stakeholder groups to participate in the formative evaluation. All key informant participants were

McCormack et al. Addict Sci Clin Pract

(2021) 16:16

Page 5 of 14

Table 3 Study components and outcomes
Study component

Outcomes

Population

Component 1—Formative evaluation and IF

Implementation outcomes

Stakeholder acceptability over time
(interviews, focus groups)
Stakeholder readiness/preparedness over time (ORCA, change
rulers)

Community and ED key informants

Component 2—Evaluation of clinical protocol

Primary clinical outcome

Received ED-initiated BUP (proportion) (EMR abstraction)

ED patients determined to be eligible
for and willing to receive EDinitiated BUP

Secondary outcomes—Process
measures and additional proportions of interest

Opioid screen completed

ED patients (adult)

Opioid Screen positive

Screen completed

ED-initiated BUP eligibility assessment completed

Opioid Screen positive

ED-initiated BUP eligible

Opioid Screen positive

ED-initiated BUP eligible and willing ED-initiated BUP eligible

Component 3—Patient-participant
outcomes

Received a facilitated referral for
treatment

ED-initiated BUP received

Received a facilitated referral for
treatment

Eligible and willing for ED-initiated
BUP, but not received

Main secondary outcome

Engaged in formal addiction treatment 30 days after the index ED
visit (proportion) (patient selfreport with clinic confirmation)

Enrolled patient-participants who
received ED-initiated BUP (secondarily, BUP non-receivers)

Secondary outcomes—Patient
treatment

Value and change from baseline for
the following:
Substance use (self-report via TLFB,
UDS)
Overdose events (self-report)
Healthcare utilization (self-report
Heath Services Utilization Form)
Quality of life (EQ5D)
Treatment satisfaction and acceptability (self-report)
Initial contact with medication
provider (9-day)

Enrolled patient-participants who
received ED-initiated BUP (secondarily, BUP non-receivers)

consenting, English-speaking adults from the below
stakeholder groups who are not prisoners:
1) ED/Hospital leadership, providers, and staff across
multiple disciplines (e.g., nurses, social workers,
physicians, Advanced Nurse Practitioners, Physician
Assistants, ED techs, pharmacists, medical directors,
executive hospital leadership) at each ED site.
2) Community providers, leadership and staff involved
in the provision of office based BUP, community
treatment, and/or at opioid treatment programs
(OTPs).
3) Other community leaders and stakeholders (e.g.,
EMS, fire department, police, local government leadership, community advocacy groups, etc.).
4) ED patients with OUD.
Survey participants: Approximately 150 members of
groups 1–2 above (including those who participated
in focus groups), were invited to complete structured

assessments during the formative evaluation and at
study close. Respondents were compensated $10 for
survey completion.
Participants contributing to qualitative data: A purposive sample of approximately 60 individuals from
groups 1–4 above across all 3 sites were recruited to
participate in qualitative interviews or focus groups
(based on scheduling availably) during the formative
evaluation and at study close. We recruited participants that spanned disciplines and included individuals who were likely to support or resist the introduction
of ED-based BUP initiation program by querying site
leadership as well as focus group/interview participants
themselves. Attempts were made to recruit equally
across all 3 sites. Focus group participants in category
4 (ED patients with OUD) were selected based on ED
patient availability and willingness during time periods
of scheduled focus groups. A minority of the group 4
qualitative with OUD patient participants were selected
from previously enrolled patient-participants. Each
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participant received a $25 gift card for participation in
a focus group/interview.
All ED patients: Administrative and health record
data for all adult patients presenting to each of the study
EDs during the 6-month study program evaluation and
enrollment period were examined to identify patients
with OUD and potential patient-participants as well as to
evaluate fidelity to clinical actions and processes.
Patient-participants: During the 6-month evaluation
period, we intended to enroll 60 patient-participants to
participate in two research visits (baseline and Day 30
post ED discharge). Given that none of the EDs had existing ED-initiated BUP programs and the limited data on
which to base precision estimates, we planned to increase
enrollment to our staff ’s maximum potential capacity to
recruit and retain (approximately 180 patients), should
more robust recruitment be possible. Patient-participants were adult ED patients who were determined by
ED clinical staff to be eligible for and willing to receive
BUP according to criteria in site-specific clinical protocols (hereafter, referred to as “candidates” to receive EDinitiated BUP). Operationally, to be considered a BUP
candidate, explicit documentation in the medical chart
indicating patient interest in BUP and clinical eligibility
was required unless this could be reasonably inferred by
documented clinical actions (e.g., patient receives EDinitiated BUP). Patient-participants must have been willing and able to provide written informed consent, speak
English sufficiently to understand study procedures, and
provide two unique forms of contact, and were excluded
if currently engaged in medication for OUD (MOUD)
treatment or opioid-requiring pain management, a participant in a substance use intervention study, medically
or psychiatrically unstable, or a prisoner. We employed a
recruitment strategy to ensure patient-participant enrollment would be relatively even over time and between
sites, and that the ratio of patient-participants who
receive BUP to those who do not would be at least 2:1,
as we anticipated that some eligible patients would not
receive buprenorphine. Participants were compensated
$75 upon completion of screening and baseline and $100
upon completion of the 30-day follow-up visit.

Study component 1: implementation facilitation
Implementation Science, defined by the National Institute of Health as “the study of methods to promote the
integration of research findings and evidence into healthcare policy and practice” [10] provides an organized
approach and tools to fill the gap between the need and
provision of ED-initiated BUP and ongoing medication
treatment for OUD. We employed the IF methodology,
using procedures adapted from those used in CTN-0069
Project ED Health [8], which are based on a manualized
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program developed by Kirchner and colleagues [11]. For
this systems-level intervention, study external facilitators
engage with stakeholders and identify and collaborate
with local champions to conduct a formative evaluation,
develop and refine clinical protocols resources, perform
academic detailing and staff education, lead a learning
collaborative, and facilitate performance monitoring and
feedback. These elements of our IF approach are outlined
in Table 4 and specified further below.
Formative evaluation: Throughout the study timeline,
we used a participatory action research [12] approach,
adapted from the IF strategy in CTN-0069 Project ED
Health [8], to iteratively gather information from stakeholders and key informants to inform the planning
and execution of actions to refine procedures and support implementation and enhance acceptability. This
was achieved by holding regular stakeholder meetings
and conducting and repeating qualitative and quantitative assessments with clinical and administrative staff,
patients, and other stakeholders. IF was guided by formative evaluation, an iterative process that uses these mixed
methods to tailor training, support, and overall implementation of the clinical protocol to each specific site.
Formative evaluation included site-specific organizational, provider, and patient factors potentially impacting
uptake of provision of ED-initiated BUP [11]. Throughout
the implementation period, we rigorously documented
summary findings, notable observations, and preliminary
themes from various sources (interviews, focus groups,
stakeholder meetings, learning collaboratives, IF logs
maintained by research staff at each site, monthly clinical staff meetings at each site, and other feedback), which
we entered into action research matrixes. We had multiple standing calls per week with research staff and various stakeholders to review, provide feedback, and add
to these data. By organizing and continuously updating
data triangulated from multiple sources along with corresponding subsequent actions consistent with a Rapid
Assessment Process[13], these matrixes provided the
structure to rapidly synthesize preliminary data and
iteratively refine clinical protocols and implementation
strategies.
PARiHS framework: Building on the mixed-methods
analysis conducted during the formative evaluation, we
used the Promoting Action on Research in Health Services (PARiHS) framework to tailor IF for site-specific
needs [14–17]. We characterized the facilitators and barriers identified by the key informants according to the
PARiHS sub-elements of patient and clinical experience
(communication, knowledgeable and empathetic providers), receptive context (resources to provide addiction
treatments), and culture (value of team-based approach)
identified. PARiHS was used to further explicate and
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Table 4 Implementation facilitation roles and activities
Role

Definition

External facilitators (EF)

Study investigator content experts (McCormack, Hawk) facilitate activities (as described below) designed
to promote implementation of the clinical protocol for OUD tailored to the clinic-specific needs

Local champions (LC)

LCs were ED clinical staff who help promote ED-initiated BUP with referral for treatment. LCs will serve the
primary liaison between the ED and the EFs. LCs will lead implementation efforts on the ground, identify
site-specific needs, and work with department and hospital leaderships to draft policies and secure
approvals

ED staff and providers

All ED staff and providers were invited to participate in the Learning Collaborative, receive training/education, and provide feedback on the implementation of clinical protocol

Activity

Definition

Formative evaluation

Using mixed-methods, the research team identify evidence, context, and facilitation-related factors
impacting the provision of ED-initiated BUP with referral for treatment in the community and use these
data to refine and evaluate the effectiveness of the IF

Advising on ED-initiated BUP Clinical
Protocol Development

Serving in an advisory and consultant capacity, EFs work with the clinical sites to develop a clinical protocol for nonmedical opioid use screening and ED-initiated BUP with facilitated referral tailored for their
site. EFs will provide ongoing consultation to help monitor, support, and refine implementation

Assistance with facilitated referrals

EFs will work with LCs to identify community OUD treatment providers and create site-specific referral lists
of medication treatment providers and other supportive resources for patients with OUD. EFs will also
assist with identifying a practical approach to facilitating referrals

Stakeholder engagement

Stakeholder engagement took place in the form of in-person meetings at the administrative, provider,
community and patient levels. Efforts at increasing engagement were informed by the focus groups and
qualitative interviews and supported by the efforts of the LCs

Tailor program to site

The IF strategy were tailored to the local site as informed by the formative evaluation, involvement of the
LCs, and with feedback from all ED staff and providers

Provider education and academic detailing All ED providers were offered educational sessions on OUD and BUP training, specifically tailored to each
provider’s tasks. We will address practical issues such as efficient use of the EMR for prompts, provide
tools and web-based resources, and share patient monitoring strategies
Performance monitoring and feedback

We worked with ED leaders and other members of the ED staff to incorporate clinician performance
related to BUP-initiation and facilitated referral into the department’s standard quality improvement and
feedback practices. Sites were provided aggregate feedback on screening for nonmedical opioid use,
adherence to clinical actions, eligible patients receiving BUP in the ED and referred patients’ enrollment
in ongoing treatment

Learning collaborative

A Learning Collaborative was formed by inviting each of the site’s LCs and other ED stakeholders to participate in weekly conference calls to promote shared learning regarding issues promoting and hindering
implementation of addiction treatment. Topics will include DATA 2000 “x-waiver” requirements, strategies
for launching a new clinical initiative, existing models of ED-BUP, and BUP education, among others

design the IF, guide the ongoing formative evaluation,
and revise the strategy in an iterative manner to improve
implementation success. We iteratively assessed processes and received feedback from providers, patients,
and other stakeholders to amend and improve the feasibility, acceptability, and uptake of ED-initiated BUP in a
way that is sustainable across the different sites.
Clinical protocols and resources development: Our
clinical protocol development strategy included developing clinical protocols containing critical clinical
actions of the intervention to expected fidelity (i.e.,
identifying and appropriately assessing patients for
treatment, initiating BUP treatment, facilitating referral, etc.) along with aspects that may be adapted by
local sites to aid implementation. The Yale clinical protocol, previously tested by D’Onofrio et al., served as
the base case model [4]. In partnership with multidisciplinary teams at each site, we adapted clinical practices

and available information about SL-BUP and XR-BUP
to site-specific clinical protocols and implementation
strategies. The resulting algorithms provided guidance
related to the choice of formulation, dose, timing, and
other decisions, including whether home induction
with SL-BUP is appropriate. The site-specific clinical
protocols were refined throughout the entirety of the
study to improve programmatic feasibility, acceptability, and effectiveness using the Rapid Assessment Process of collecting and synthesizing data [6]. This form
of participatory action research is an intensive, teambased approach, involving rapid cycles of gathering
information, planning actions, implementing changes,
and collecting feedback to inform subsequent revisions.
It is ideally suited for this study because it allowed us
to explore and test modifications to how, when, and
by whom critical clinical actions are performed across
these markedly different ED settings with unmet
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treatment burden, and to disseminate generalizable
information expeditiously to support OUD treatment
where it is needed most.
Resource development: Similarly, serving in an advisory
capacity, external facilitators worked with local champions to identify potential OUD treatment providers for
ongoing treatment and draw on existing resources to
support programmatic implementation. These resources
were to simply and practically help providers gain competence and confidence in identifying candidates for EDinitiated BUP, performing pre-induction assessments,
inducting patients onto BUP in accordance with clinical
prescribing guidelines and facilitating referral for treatment. External facilitators identified existing resources
and technologies that aid effective implementation by,
for example, aiding to engage and train clinical staff, provide real-time clinical guidance/support, reduce stigmarelated barriers, and improve clinical documentation and
quality assurance monitoring.
Education and academic detailing: External Facilitators, who work clinically as emergency medicine physicians and have expertise in initiating BUP in the ED
and formal training in academic detailing (https://www.
narcad.org), conducted site visits and met with individuals and/or in small groups with clinical staff working in the ED at each study site to perform academic
detailing, which involves sharing unbiased information
about patient assessment and treatment with the goal
of improving quality of care [11]. Clinicians who may
be involved in the initiation or continuation of BUP or
assisting with the referral process were offered educational sessions on OUD and BUP training, specifically
tailored to each provider’s tasks. We addressed practical issues, such as efficient documentation, and offered
opportunities and facilitated training, including completing the Drug Addiction Treatment Act of 2000 (DATA
2000) waiver (i.e., X-waiver) for BUP prescribing. Data
from the formative and ongoing evaluation were used to
amend strategies to enhance implementation.
Learning collaborative: A weekly Learning Collaborative was formed by inviting each of the site’s local
champions, and other key stakeholders, to participate in
weekly, interactive conference calls to promote shared
learning regarding issues promoting and hindering
implementation of addiction treatment. This call provided a dedicated time to discuss site-specific clinical
updates, challenges and possible solutions for implementation of addiction services.
Performance monitoring and feedback: We worked with
ED leaders and other members of the ED staff to incorporate clinician performance related to BUP-initiation
and facilitated referral into the department’s standard
continuous quality improvement and feedback practices.
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Study component 1: IF assessments and measures
Site assessments: Site characteristics surveys were completed by clinical directors or their designees for each
site at the start and end of the study timeline to gather
information describing the ED, hospital, and community
treatment programs, including staff characteristics (age,
sex, training, permanent/Locum Tenens, etc.), existing
and potential treatment services available in the ED and
community, and patient payer mix and demographics.
Included in this were the number of providers who have
obtained DATA 2000 waivers to prescribe BUP.
Provider and staff quantitative assessments (surveys):
The quantitative components included anonymous
web-based surveys of ED and community treatment setting providers and other staff. An introductory email
and reminders containing a link to the survey was sent
on behalf of their respective leadership explaining the
purpose of the survey. When completing the survey,
respondents consent for their information to be reported
in aggregate. Baseline surveys were completed prior to
IF activities and repeated at study close, including the
Organizational Readiness to Change Assessment (ORCA)
and change rulers which were both previously adapted to
assess readiness and preparedness to provide ED-initiated BUP [18]. Based on the PARiHS framework, these
measures were used to determine evidence- and contextrelated strengths and weaknesses in organizational and
personal readiness to implement BUP and referral and
to tailor the IF. Each respondent also completed a brief
Individual characteristics survey that gathers information
on clinical role, training, treatment of OUD and general
demographic information.
Key informant qualitative assessments: focus groups
and interviews: The qualitative components, consisting
of semi-structured interviews and focus groups, provided a more in-depth understanding of feasibility and
acceptability, including barriers, facilitators, and other
needs to support implementation, from the perspectives
of ED and community treatment setting staff as well as
ED patients and community stakeholders [key informant
participants]. We chose to use focus groups given their
suitability for generating data from multiple perspectives
regarding the organizational and individual level factors
impacting complex processes when available, and used
one-on-one semi-structured interviews for information
gathering to allow for the broadest inclusion of perspectives when it was neither feasible nor practical to arrange
a suitable focus group [19]. The interview guide used in
CTN-0069 Project ED Health [8] was adapted to specifically elicit perspectives about BUP and better understand how the characteristic differences of the sites and
the population served by them may influence programmatic implementation and effectiveness. All participants
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provided verbal informed consent to participate in a
60-min focus group/interview that was recorded and
transcribed verbatim.

Study component 2: evaluation of clinical protocol
implementation (primary outcome)
Process measures related to the clinical protocol as well
as reasons for non-completion and/or ineligibility were
abstracted from the hospital EMR. These data allowed for
measurement of clinical protocol adherence to support
both overall study goals and site-specific internal continuous quality improvement efforts. This dataset provided
the study primary outcome, which we define from Aim
2 as the proportion of unique patients who received EDinitiated BUP amongst patients who were determined to
be eligible for and willing to receive ED-initiated BUP.
Under a waiver of consent, research staff reviewed data
for all patients presenting to the ED at each study site
during the study enrollment period. Individual charts of
those patients screening positive for nonmedical opioid
use were reviewed to collect documentation of adherence
to components of the clinical protocol using an electronic
data capture system managed by the Data and Statistics
Center at the Emmes Company. We generated proportions along the cascade of clinical actions and measure
fidelity to critical and non-critical clinical actions, including but not limited to the following: screening for nonmedical opioid use, assessment of OUD, assessment
of opioid withdrawal, assessment of pregnancy among
women, initiation of BUP, prescription for ongoing BUP,
and facilitation of referral.
Rigorous research staff training was followed by weekly
meetings to review cases and quality assurance monitoring. A second member of the research team independently performed medical record abstraction of a
random sample of approximately 10% of the logs created (i.e., 10% of the days in the enrollment period). The
second independent reviewer was masked to the information obtained by the first reviewer. Once the second
review was completed and entered, the data system
performed a comparison of the two logs and generated
discrepancy reports. Inter-rater agreement between the
two independent coordinators for the chart abstraction
required for the primary outcome data was measured by
generating a kappa statistic. Periodic meetings with chart
abstractors and other team members (i.e., site investigators) were held to resolve discrepancies, review coding
rules, and monitor performance.
Study component 3: patient‑level outcomes
We explored our secondary patient-level outcomes
(engagement in ongoing treatment, drug use, overdose
events, healthcare use, quality of life, acceptability,
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etc.) by recruiting ED patients who were candidates
for ED-initiated BUP to participate in two research
visits. Research staff worked rotating shifts in the ED,
providing coverage on weekdays, evenings and weekends. Study staff did not approach patients (or their
providers) for potential study entry until all clinical
actions included in the site’s ED-initiated BUP protocol were completed (i.e., screening, treatment initiation, and referral) or after the ED visit was completed.
Thus, if any actions remained incomplete and/or the
research screening could not occur during the index
ED visit, the study coordinator approached the patient
after discharge from the ED. This decision to delay our
approach was deliberated at length. Although it added
considerable challenges to patient recruitment, it minimized the risk of research activities influencing the
clinical processes being evaluated; therefore, it minimized potential confounding of our primary implementation outcome, which is evaluated via EMR abstraction
without patient-participant enrollment. Potential study
participants who presented to the ED outside of
recruiting hours or could not be approached in person were contacted and screened telephonically using
contact information available in the EMR. At each site,
patients were able to opt-out of such communications.
Remotely approached potential participants who were
eligible for and interested in study participation were
scheduled for written informed consent and baseline
assessments to be completed in person within 7 days of
their ED discharge.
Baseline visit: Adult ED patients who were determined
to be eligible for and willing to receive BUP by ED clinicians according to site-specific clinical protocols were
approached by research staff to be screened for potential study participation. Both candidates who did and did
not receive BUP were enrolled to learn about the acceptability of and barriers to initiation of BUP in the ED.
Before performing any study assessments, research staff
requested the patient’s verbal consent to assess eligibility
using an IRB-approved verbal consent script. After the
patient provided verbal consent, research staff collected
basic demographic information and confirmed that the
candidate met all the inclusion criteria and none of the
exclusion criteria using an eligibility checklist. To participate, eligible candidates provided written informed
consent and signed an authorization for release of information for the purpose of confirming treatment engagement at day 30 with treatment facilities. After providing
their written informed consent, enrolled patient-participants provided a urine sample for drug testing and completed coordinator-administered assessments (described
below), which required approximately 30–60 min. Upon
completion of the baseline visit, patient-participants were
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scheduled for a follow-up research visit to occur 30 days
after the index ED visit.
Follow-up research visit (Day 30): All patient-participants were asked to return to a research office on the
hospital campus for a follow-up research visit 30 days
after their index ED visit. Study coordinators used multiple forms of contact and locator information collected
during enrollment to remind patient-participants of the
visit; IRB-approved scripts for telephone, email, and
other messaging were used for all communications to
support study retention. At the follow-up visit, patientparticipants provided a urine sample for drug screening
and repeated the assessments completed at the baseline
visit as well as additional questions related to engagement
in formal addiction treatment and treatment satisfaction.

Patient‑participant measures
The study team obtained data by participant self-report,
EMR abstraction, direct contact with treatment providers, and review of the Prescription Drug Monitoring
Program (PDMP) database. We assessed a range of pretreatment participant characteristics derived from our
team’s previous and ongoing studies, including CTN0069 Project ED Health [8], and the Substance Abuse and
Addiction Collection of the PhenX Toolkit that includes
measures that are being adopted across NIDA-funded
research (Table 5). Baseline assessments and patient
reported measures were used to ensure that patients
met eligibility criteria, that important predictor variables
are assessed, and that we have a baseline for changes in
patient-reported outcomes. Biologic specimens included
urine samples analyzed for opiates, methadone, oxycodone, cocaine metabolite (benzoylecognine), barbiturates, methamphetamine, amphetamine, marijuana and
benzodiazepines. Fentanyl was tested using the BNTX
Rapid Response™ fentanyl urine strip test, with a detection level of 20 ng/ml norfentanyl (for forensic use only)
[20]. Research staff confirmed participant-reported
engagement in formal addiction treatment on the 30th
day after the index ED by contacting the treating provider/facility reported by the participant. Additionally,
for each participant, study staff reviewed the EMR and
PDMP database to abstract data on treatment delivered
during the index ED visit and hospitalizations, ED visits,
and prescriptions for BUP and other opioid analgesics
filled in the subsequent 30-day period.
Data and safety monitoring

Because this prospective study examined BUP treatment
initiation and the impact of ED-initiated BUP on engagement in addiction treatment and drug-use-related outcomes, and the use of these medications is in line with
community practice, safety reporting was limited to
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Table 5 Schedule of research assessments for patientparticipants
Assessment

Screening Baseline Day 30

Eligibility and enrollment
Verbal consent

X

Prisoner status assessment

X

Demographics

X

Eligibility summary

X

Enrollment (inclusion/exclusion)

X

General
Written informed consent and medical
release

X

Additional demographics

X

Locator information form

X

DSM-5 checklist for OUD

X

Other substance use [21]

X

EuroQol-5 dimensions (EQ-5D) [22]

X

Motivations, attitudes and expectations

X

Study completion

X

X
X

Health services
Inpatient utilization

X

X

Outpatient utilization

X

X

Health status [23–25]

X

X

Healthcare visit logistics

X

ED visit review

X

ED visits and hospitalizations

X

Process outcomes
Engagement in treatment

X

Prescription drug monitoring
Treatment decision

X
X

Treatment satisfaction/acceptability

X

Opioid outcomes
Timeline follow-back, 7-day (TLFB) [26,
27]

X

X

Urine drug screen

X

X

Overdose events and risk factors

X

X

X

X

Safety
Safety events

recording any opioid overdose that occurs on study, any
death, and healthcare utilization including ED visits and
hospitalizations. Each of the sites and communities have
established practices for managing medical and psychiatric emergencies, and those established practices were followed per standard of care in each community.
An independent study monitor was designated to
review all safety events for this protocol and determine if
reporting to NIDA, the DSMB and/or regulatory authorities was required. Reports were generated by the data and
statistics team at the Emmes Company and presented for
DSMB meetings. An independent CTN DSMB examined
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accumulating data to assure protection of participants’
safety and assure that scientific goals were being met.
The CTN DSMB is responsible for conducting periodic
reviews of accumulating safety trial performance and
outcome data. It determined whether there was support
for continuation of the trial, or evidence that study procedures should be changed, or if the trial should be halted,
for reasons relating to the safety of the study participants
or inadequate trial performance (e.g., poor recruitment).
Statistical analysis

Using a participatory action research approach [12] and
mixed methods, we developed, introduced, and updated
site-specific ED clinical protocols and implementation
plans for OUD screening, treatment, and referral to optimize feasibility and acceptability. Barriers to- and facilitators of implementation were explored, and the impact
of remediation efforts were assessed through sequential
qualitative and quantitative inquiry and feedback generated through the learning collaborative. Converging provider and patient perspectives with process measures and
intervention outcomes, including proportions screened,
treated, and remaining engaged in treatment, provided
explanation to contextualize and better understand feasibility, acceptability, and patient-level outcomes.
Qualitative statistical analyses (component 1)

To inform iterative changes that occurred throughout
implementation phase we used the Rapid Assessment
Process, an intensive, team-based qualitative inquiry
using triangulation, iterative data analysis, and additional
data collection to quickly develop a preliminary understanding of a situation from the insider’s perspective
[13]. Multiple team members debriefed after each focus
group, interview and stakeholder meeting to review field
notes, discuss findings and generate a summary report
collectively. These summary findings were entered into
the action research matrixes to inform real-time changes
during the implementation period and were shared with
key stakeholders. Concurrently, using the full transcripts,
we began the formal qualitative analyses, understanding
it would continue beyond the programmatic implementation and evaluation periods.
Qualitative outcomes are analyzed using directed content analysis [28]. The transcripts will be independently
reviewed, coded and analyzed by a multi-disciplinary
group. Initially transcripts will be individually reviewed
line by line in entirety and coded by multiple independent team members. Following the coding of the initial
set of transcripts, the qualitative research team will meet
to review the initial coding scheme and a codebook will
be generated by consensus, which will contain operational definitions for each code. Code generation will
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be iterative and the codebook subject to change until
no new codes are identified. Common patterns across
the dataset will be identified and will be grouped into
themes. Analysis will use the PARiHS framework, which
examines the interaction between three key elements of
Evidence, Context and Facilitation, and including subelements of patient and clinical experience (communication, knowledgeable and empathetic providers), receptive
context (resources to provide addiction treatments), and
culture (value of team-based approach). An audit trail
will be maintained. Data will be entered and organized
using Atlas.ti software.
The technique of triangulation, in which the data from
different types of ED and community staff and providers, including nursing, social work, administrators,
physicians, physician assistants and advanced nurse practitioners are interpreted in the context of each other and
patient perspectives to better understand facilitators and
barriers will be used. In addition to triangulating by different sources of qualitative data, data will be interpreted
in the context of other types of data available, including
data abstracted from EMR and administrative databases,
and quantitative data from patient-participants.
Analysis of survey responses (component 1)

Initial and changes in readiness and preparedness scores
(ORCA, readiness and preparedness rulers) as well as site
characteristics were analyzed using descriptive statistics
with pre-post comparisons, when appropriate.
Analysis of primary clinical outcome (component 2)

The second aim was to estimate the percentages and
confidence intervals of patients assessed, treated and
engaged in treatment at day 30. We defined the primary
outcome as the probability of an individual receiving EDinitiated BUP given that the individual was determined
to be eligible for and willing to receive ED-initiated BUP
using patient-level data abstracted from the EMR. We
refer to this below as the implementation probability, p.
To avoid difficulties with zero counts, we used Bayesian
estimates for the site-level implementation probability
values, assuming beta likelihood uniform prior to derive
posterior moments. That is, if there were S successes (i.e.,
BUP initiated) and F failures (i.e., BUP not initiated) for a
site, the p estimate for that site would be α/(α + β), with
estimated variance αβ/[(α + β)2 (α + β + 1)], where
α = S + 1 and β = F + 1. The overall p estimate would
be the average of the three site-level estimates. Because
the site-level p estimates are independent, the variance of
the overall p estimate would be the sum of the site-level
variances divided by 9. To construct confidence limits,
we assumed the overall estimate is roughly normal in distribution, with upper and lower 95% confidence intervals
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Fig. 1 Diagram of patient-participant enrollment and outcomes

√
given by ±1.96 ∗ Voverall . An exception to this is that we
did not allow confidence limits to stray outside (0,1).
Power/precision calculations: For our analytic plan, we
assumed that 120–180 individuals (ED patients), identified evenly from 3 sites, would be available to investigate
this primary outcome. However, there was little data on
which to base these estimates as none of the sites had
existing clinical programs to screen for or treat OUD.
Simulations conducted prior to enrollment that introduced variability among sites showed that bias was not
large for most parameters investigated, and confidence
intervals wider than 0.4 for p were not expected.
Analysis of process measures and additional proportions
of interest (component 2)

Using EMR and administrative data, we assessed fidelity to critical actions related to the program (screening, enrollment, medication administration, and
navigation to formal addiction treatment, etc.) and other
process measures of interest (Tables 3, 5). For each of
these, descriptive statistics were performed, including

proportions for categorical data and means, standard
deviations, minimum, and maximum for continuous
variables. We assessed differences between sites and the
change in proportions over time since clinical protocol
implementation.
Analysis of patient‑participant secondary outcomes
(component 3)

Analysis of the most important secondary outcome, i.e.,
the probability of being engaged in formal addiction
treatment on the 3
 0th day following the index ED visit
amongst enrolled participants who received ED-initiated
BUP, uses methods similar to that of the primary outcome. We expected to be able to enroll a sample of at
least 42–60 patient-participants with which to assess this
and other secondary outcomes (see Table 3), and actually
enrolled 40 participants who received ED-initiated BUP.
Patient-reported outcomes (e.g., illicit opioid use, overdose events, healthcare use, quality of life, treatment satisfaction) were analyzed using descriptive statistics with
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pre-post comparisons (i.e., baseline to day 30) reported,
when appropriate. We used appropriate non-parametric,
parametric, and analysis of variance statistical procedures to descriptively evaluate the key characteristics
of each study site and to evaluate comparability of baseline characteristics among patient cohorts enrolled at
each of the study sites and overall during the study. As a
non-randomized study, formal and rigorous hypothesistesting was not carried out. Findings will be reported as
noteworthy hypothesis-generating results only when
their p-values are considerably smaller than 0.05.
Missing data: The flow diagram of ED patients and
patient-participants (Fig. 1) will include information on
ineligibility and loss to follow-up. There was no loss to
follow-up for the implementation probability primary
outcome, because all necessary data is available through
the EMR. With respect to the secondary Day 30 treatment engagement proportion, patient-participants lost
to follow-up after receiving ED-BUP were counted as not
engaged in treatment, thus contribute to both numerator
and denominator instead of generating missing data.

Discussion and conclusion
The opioid epidemic has a large and growing impact on
public health and continues to decimate communities illequipped to provide substantive, timely intervention. As
the receiving center for persons experiencing overdose,
the call to action is reaching the ED. While the ED may
be an ideal and underutilized venue for addressing this
crisis, it is well-recognized to be an extremely challenging
venue for introducing, sustaining, and studying interventions. By assembling subject matter experts and involving
local stakeholders, we will translate successful elements
of efficacious interventions to EDs operating in different
contexts. These partnerships provide an opportunity for
prompt, meaningful and sustainable dissemination with
enhanced support for the intervention while it is being
developed and tested in situ. This study is designed to
provide the necessary, time-sensitive understanding of
how to identify OUD and initiate treatment with BUP in
the EDs where this intervention is most needed—which,
if successfully done, should save lives, improve outcomes,
and reduce costs to society.
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